Lower Urinary Tract Conditions COE

  • ‘Sleep Normal’ Campaign Urges Americans to End Frequent Nighttime Urination and Stop Settling for Nights of Bad Sleep

    San Francisco, CA  (UroToday.com) Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical condition called nocturia.  A new awareness campaign called ‘Sleep Normal’ launched on Monday to raise awareness of nocturia, an underdiagnosed, treatable, medical condition that forces a person to wake more than once a night to urinate. Most people have never heard of nocturia and think it is a normal part of aging, despite the negative impact interrupted sleep can have on health. The ‘Sleep Normal’ campaign urges people to talk with their doctors about addressing frequent nighttime urination.
    Published January 24, 2019
  • ACS 2018: Risk Factors for Desmopressin-Induced Hyponatremia

    Boston, Massachusetts ( UroToday.com) William N. Harris and colleagues aimed to identify new risk factors for desmopressin-induced hyponatremia in nocturia treatment. They evaluated the pooled data from six randomized controlled trials and the corresponding published results.
    Published October 26, 2018
  • As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action

    San Francisco, CA (UroToday.com) -- Nocturia Awareness Week, part of Bladder Health Month, which encourages people to take control of their urinary health. Nocturia, a treatable medical condition that forces you to wake up multiple times a night to urinate, affects nearly 50 million Americans and is a leading cause of sleep disruption.1,2 Nocturia can have mental and physical consequences, including impaired memory3 and concentration, moodiness, depression, obesity, diabetes, and a weakened immune system. However, most Americans have never heard of nocturia and think waking multiple times at night to urinate is normal.
    Published November 30, 2018
  • AUA 2018: Advances in Diagnosis & Management in Nocturia

    San Francisco, CA (UroToday.com) In this instructional course, Dr. Wein and Dr. Weiss presented a framework for the assessment of patients with nocturia. Instructors argued that cause of disease is multifactorial, and it’s crucial to consider various diagnostic tools in order to address multiple risk factors and morbidities associated with disease occurrence. Primary learning objectives included evaluation of disease etiology in relation to morbidity, mortality and economic costs; analysis of current data regarding medication use for the treatment of the disease; classification of nocturia and corresponding medical conditions based on the analysis of the voiding diary; and concurrent review of actual case studies.
    Published May 19, 2018
  • AUA 2018: Clinical Evaluation and Treatment of Nocturia is Modest at Best

    San Francisco, CA (UroToday.com)  According to Dr. Drangsholt, nocturia was defined as one or more voids at night. Primary purpose of the study was to analyze diagnostic processes and effectiveness of clinical treatment options available.   Researchers conducted a chart review of patients with a new diagnosis of nocturia from 2010 to 2016. Data on all eligible subjects were collected within a year after the first encounter. Out of all patients who were considered eligible for the study, 52% of individuals have reported previous pharmacotherapy. Voiding diary (FVC) was prescribed to half of the study participants, but patient compliance with the FVC was only at 63%.  

    Published May 19, 2018
  • AUA 2018: Extended First Uninterrupted Sleep Period (FUSP) in Nocturia Patients Following Treatment Desmopressin Using an Emulsified Microdose Formulation

    San Francisco, CA (UroToday.com)  Nocturia is associated with a number of negative health outcomes. It is linked to the reduction in quality of life (QoL), decrease in work productivity and overall health and poor mental status. Long-term consequences of nocturia include depression, high susceptibility to somatic disease, and increased risk of cardiovascular events.
    Published May 21, 2018
  • AUA 2018: Extended First Uninterrupted Sleep Period in Elderly Patients Following Treatment with AV002, an Emulsified Low Dose Vasopressin Analog for Nocturia

    San Francisco, CA (UroToday.com) Nocturia, characterized by the need to wake at night to urinate, has gained increasing exposure in the urologic community due to its high prevalence and negative impact on quality of life. It often is associated with disrupted sleep, resulting in decreased productivity, poorer overall and mental health, increased risk of falls and fractures, and increased mortality. Studies have also shown it leads to decreased concentration and cognitive function, poorer moods, and reduced energy, as well as increased susceptibility to disease. Unfortunately, treatment options for nocturia remain limited and/or associated with adverse side effects.
    Published May 23, 2018
  • AUA 2018: What’s Keeping You Up at Night? Nocturia as a Primary Complaint

    San Francisco, CA (UroToday.com) In this presentation, Lindsey Kerr, MD, provided an overview of nocturia in men and women, described disease prevalence and its’ consequences, and introduced current treatment methods including pharmacotherapy and behavioral modifications. Nocturia was defined as waking up at night one or more times to void. This condition is associated with decreased quality of life and increased chance of developing comorbidities, which makes diagnosis even more challenging.
    Published May 19, 2018
  • Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.

    Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, pelvic ischemia, prostatic chronic inflammation and associated comorbidities in the pathophysiology of storage LUTS.

    Published February 20, 2018
  • Desmopressin for treating nocturia in men.

    To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men.

    We performed a comprehensive search using multiple databases and abstract proceedings with no restrictions on the language of publication or publication status, up until August 2017.

    Published March 5, 2018
  • Development of a new patient-reported outcome (PRO) measure on the Impact of Nighttime Urination (INTU) in patients with nocturia-Psychometric validation.

    To psychometrically evaluate the Impact of Nighttime Urination (INTU) questionnaire, a new patient-reported outcome measure developed to assess the impact of nocturia on health and functioning in a multicenter, behavioral modification (fluid restriction) study.

    Published April 2, 2018
  • Diagnostic and therapeutic recommendations for patients with nocturia.

    Nocturia is defined as the urge to urinate at night when the micturition was directly preceded and followed by sleep. Due to its negative impact on the quality of life of patients, an effective treatment for this disease has become a significant therapeutic challenge.

    Published February 27, 2018
  • Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials - Beyond the Abstract

    The Journal of Urology recently published a paper entitled “Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials.” The two studies, DB3 and DB4, were the pivotal, registration trials which formed the basis for FDA approval and shared similar designs, eligibility criteria, methods, endpoints and analytical approaches.
    Published June 7, 2018
  • ICS 2018: Extended First Uninterrupted Sleep Period for Older Adults Following Treatment with AV002, an Emulsified Microdose Vasopressin Analog

    Philadelphia, PA (UroToday.com) Nocturia is associated with a number of negative health outcomes. It is linked to the reduction in quality of life (QoL), decrease in work productivity and overall health. First uninterrupted sleep period (FUSP) is a critical determinant of sleep quality. It is defined as the time from bedtime to first nighttime urination or first awakening when no void occurred. According to the presenter, the risk of nocturia increases with age. Thus it is crucial to examine possible treatment solutions in the elderly population, who in general have more comorbidities and concomitant medications. 
    Published August 29, 2018
  • ICS 2018: Safety and Efficacy of Desmopressin Orally Disintegrating Tablet 25/50mg in Patients with Nocturia and Mild Daytime Urinary Symptoms

    Philadelphia, PA (UroToday.com) While oral desmopressin is a common treatment option in patients with nocturic episodes, data are scarce in patients who report both nocturia and daytime lower urinary symptoms. Dr. Weiss provided an overview of the study assessing safety and efficacy of the medication in the subgroups with nocturnal polyuria (NP) only and NP with overactive bladder (OAB) or benign prostatic obstruction (BPO).
    Published August 29, 2018
  • Management of Nocturia | SUFU 2018

    Austin, TX (UroToday.com) A panel discussion on the management of nocturia, A Nocturia Clinical Pathway was held and Dr. Tamsin J. Greenwell began by addressing medical risk factors for nocturia.  He states the most important thing is to try and address the etiology of the nocturia.  The clinician should make note of the patient’s fluid intake, especially alcohol and caffeine.  Assess the patients sleep using the Epworth Sleepiness Scale (ESS).  Assess cardiovascular function, as well as BMI and hip to waist ratio, as these may be risk factors for obstructive sleep apnea.  Obtain a frequency volume chart.  Finally, obtain baseline labs: a urinalysis to exclude DM, UTI, or hematuria.  Obtain renal function, hemoglobin A1c, liver function tests, lipid profile, and PSA, if indicated.  

    Published March 2, 2018
  • Nocturia and associated mortality: observational data from the REDUCE trial.

    Nocturia (voids arising from sleep) is a ubiquitous phenomenon reflecting many diverse conditions but whether it has significance in its own right remains uncertain. We examined whether nocturia was an independent risk factor for mortality METHODS: These were observational analyses employing primarily North American and European participants and included 7343 men, aged 50-75 years participating in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial.

    Published September 24, 2018
  • Sleep and Nocturia in Older Adults.

    Older adults frequently experience nocturia and sleep disturbance concurrently, and problems with sleep resulting from nocturia are a major factor accompanying the bother associated with nocturia. A multicomponent treatment strategy is usually warranted.

    Published February 21, 2018
  • SUFU 2018: Management of LUTS in the Male Underactive Bladder

    Austin, TX (UroToday.com) A point-counterpoint panel discussion on the topic of the management of lower urinary tract symptoms (LUTS) in the male underactive bladder was held at SUFU 2018 in Austin, Texas.  The moderator, Dr. Gousse, presented two difficult cases from his practice. The most recent definition of underactive bladder (UAB) states, “UAB is characterized by a slow urinary stream, hesitancy, and straining to void with or without a feeling of incomplete bladder emptying, sometimes with storage symptoms.”   We believe that the prevalence of UAB is 11-44%, but the true prevalence is really unknown. 
    Published March 2, 2018
  • SUFU 2018: Pathophysiology of Nocturia

    Austin, TX (UroToday.com) Jeffrey P. Weiss, MD gave a State of the Art lecture on the pathophysiology of nocturia.   He describes the most important step to the evaluation of nocturia is a 24 hour voiding diary. 

    Published March 2, 2018
  • Systematic review of proposed definitions of nocturnal polyuria and population-based evidence of their diagnostic accuracy.

    Background Evidence of diagnostic accuracy for proposed definitions of nocturnal polyuria is currently unclear. Purpose Systematic review to determine population-based evidence of the diagnostic accuracy of proposed definitions of nocturnal polyuria based on data from frequency-volume charts.

    Published February 28, 2018
  • The Launch of NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

    Truckee, CA (UroToday.com) Innovative product now available in the United States for a condition that interrupts sleep for over 40 million Americans - Avadel Pharmaceuticals plc announced the launch of NOCTIVA™ (desmopressin acetate), an emulsified microdose Nasal Spray. NOCTIVA is the first and only FDA-approved treatment proven to help adults with nocturia due to nocturnal polyuria, a condition which causes the kidneys to overproduce urine at night.1 NOCTIVA safely and effectively treats a condition that causes more than 40 million Americansto wake two or more times per night to use the bathroom, and prevents them from getting a good night’s sleep.
    Published May 1, 2018
  • The Medical Condition 72 Percent of Americans Don’t Know About is Stealing Sleep and Disrupting Lives, Survey Shows

    San Francisco, CA (UroToday.com) -- Sleepless nights can be costly. They interfere with daily activities and work productivity and leave one feeling tired and irritable. If left untreated, sleep loss can result in serious medical consequences. A leading cause of sleep loss is a medical condition called nocturia,which a staggering 72 percent of Americans have never heard about, according to a new national online survey of 2,040 U.S. adults conducted by The Harris Poll, and endorsed by Caregiver Action Network, National Association for Continence, Prostate Conditions Education Council, and The Simon Foundation for Continence.
    Published September 13, 2018
  • The Relationship Between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the National Health and Nutrition Examination Survey (NHANES).

    It is well established that sleep disorders (SDs) are associated with the prevalence of nocturia in men. While previous literature supports that patients with SDs are at increased risk of nocturia, the risk of daytime lower urinary tract symptoms (LUTS) has not been well established.

    Published February 22, 2018

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.